Olr375 inhibitors represent a specific class of compounds that interact with the olfactory receptor Olr375, a member of the G protein-coupled receptor (GPCR) family. These receptors are part of a vast network involved in the detection of volatile molecules, playing a crucial role in the sensory perception of smell. Olr375, like other olfactory receptors, is embedded in the membrane of olfactory sensory neurons, where it initiates a signaling cascade upon binding with specific ligands. Inhibitors targeting Olr375 function by interfering with the receptor's ability to bind its native ligands or by preventing the downstream signaling mechanisms that follow ligand-receptor interaction. The inhibition of Olr375 can be achieved through various mechanisms, such as competitive inhibition, where the inhibitor competes with the natural ligand for the active binding site, or allosteric inhibition, where the inhibitor binds to a different site on the receptor, inducing a conformational change that reduces the receptor's activity.
The study of Olr375 inhibitors is of significant interest due to their potential to modulate specific olfactory pathways, thereby providing insights into the fundamental processes of olfactory perception and signal transduction. By examining the structural features of Olr375 and its inhibitors, researchers can gain a deeper understanding of the molecular interactions that govern receptor activity. This includes the identification of key amino acid residues involved in ligand binding, the conformational dynamics of the receptor in its active and inactive states, and the impact of inhibitor binding on these structural states. Additionally, research into Olr375 inhibitors contributes to broader efforts to elucidate the structure-function relationships within the GPCR superfamily, as olfactory receptors share many common features with other GPCRs involved in various physiological processes. Understanding these relationships is crucial for advancing our knowledge of receptor biology and the molecular mechanisms underlying sensory perception.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Targets multiple kinases, potentially altering pathways in tumor growth and angiogenesis. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Src family kinase inhibitor, potentially alters signal transduction in various cancers. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
HDAC inhibitor, potentially affects gene expression and protein acetylation processes. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $75.00 $121.00 | 33 | |
EGFR inhibitor, potentially disrupts signaling in non-small cell lung cancer. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
mTOR inhibitor, potentially impacts cell growth, proliferation, and survival pathways. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Dual EGFR and HER2 inhibitor, potentially affects signaling in breast cancer. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Multi-kinase inhibitor, potentially affects angiogenesis and tumor growth. | ||||||
Afatinib | 439081-18-2 | sc-364398 sc-364398A | 5 mg 10 mg | $114.00 $198.00 | 13 | |
Irreversible EGFR inhibitor, potentially affects cell signaling in lung cancer. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Targets multiple kinases, potentially affects growth and angiogenesis in colorectal cancer. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
EGFR inhibitor, specifically targets T790M mutation in lung cancer. | ||||||